Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | PPM1B | O75688 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1634434 | 0.98 | ALDH1A1 (0.49) | ALDH1A1LMNAKDM4ETP53PPM1B | |
| SCHEMBL11010717 | 0.77 | ALDH1A1 (0.47) | ALDH1A1LMNAMEN1KMT2ATP53 | |
| SCHEMBL11479882 | 0.76 | LMNA (0.60) | ALDH1A1LMNAMEN1KMT2AKDM4E | |
| SCHEMBL9796975 | 0.76 | ALDH1A1 (0.46) | ALDH1A1LMNAMEN1KMT2AKDM4E | |
| SCHEMBL11458805 | 0.73 | LMNA (0.62) | ALDH1A1LMNAMEN1KMT2AKDM4E | |
| SCHEMBL6268367 | 0.72 | UGT2B7 (0.33) | — | |
| SCHEMBL1635419 | 0.72 | UGT2B7 (0.33) | — | |
| SCHEMBL7641506 | 0.72 | LMNA (0.56) | ALDH1A1LMNAKDM4ETP53 | |
| SCHEMBL3754080 | 0.72 | ALDH1A1 (0.46) | ALDH1A1LMNAMEN1KMT2AKDM4E | |
| SCHEMBL3747168 | 0.72 | ALDH1A1 (0.46) | ALDH1A1LMNAMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932245-B2 | Spirocyclopropyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES (US) | 2011-04-26 | — | — | US | disclosed |
| EP-1558230-B1 | SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LAB (US) | 2008-12-31 | — | — | EP | disclosed |
| US-20040204396-A1 | Spirocyclopropyl amides and acids and their therapeutic applications | ABBVIE INC. | 2004-10-14 | — | — | US | disclosed |
| US-20040077616-A1 | Spirocyclopropyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077616-A1 | Spirocyclopropyl amides and acids and their therapeutic applications | SCN1A, SCN1B, SCN10A | ALDH1A1 85/4885LMNA 1139/4885MEN1 1497/4885 |
| US-20040204396-A1 | Spirocyclopropyl amides and acids and their therapeutic applications | SCN1A, SCN1B, SCN10A | ALDH1A1 85/4885LMNA 1139/4885MEN1 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.